FGFR1 amplification is present in 20% of squamous cell lung cancer,[11, 12] 5% of small cell lung cancer [13] and in 10% of breast cancers,[14, 15] FGFR2 amplifications or mutations in about 5% of gastric cancer,[16] FGFR3 mutations in 10-15% of muscle invasive bladder cancer [17, 18]. This evidence concerns the gene FGFR2 and breast cancer.